ESPR vs. KNSA, GPCR, ARQT, NRIX, INDV, ARDX, ARVN, SNDX, VIR, and ANIP
Should you be buying Esperion Therapeutics stock or one of its competitors? The main competitors of Esperion Therapeutics include Kiniksa Pharmaceuticals (KNSA), Structure Therapeutics (GPCR), Arcutis Biotherapeutics (ARQT), Nurix Therapeutics (NRIX), Indivior (INDV), Ardelyx (ARDX), Arvinas (ARVN), Syndax Pharmaceuticals (SNDX), Vir Biotechnology (VIR), and ANI Pharmaceuticals (ANIP). These companies are all part of the "pharmaceutical products" industry.
Esperion Therapeutics vs.
Esperion Therapeutics (NASDAQ:ESPR) and Kiniksa Pharmaceuticals (NASDAQ:KNSA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, community ranking, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.
Esperion Therapeutics received 454 more outperform votes than Kiniksa Pharmaceuticals when rated by MarketBeat users. Likewise, 70.15% of users gave Esperion Therapeutics an outperform vote while only 65.02% of users gave Kiniksa Pharmaceuticals an outperform vote.
47.4% of Esperion Therapeutics shares are held by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals shares are held by institutional investors. 1.0% of Esperion Therapeutics shares are held by company insiders. Comparatively, 54.6% of Kiniksa Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Esperion Therapeutics presently has a consensus target price of $6.75, suggesting a potential upside of 262.90%. Kiniksa Pharmaceuticals has a consensus target price of $36.60, suggesting a potential upside of 85.41%. Given Esperion Therapeutics' higher probable upside, equities research analysts plainly believe Esperion Therapeutics is more favorable than Kiniksa Pharmaceuticals.
Kiniksa Pharmaceuticals has higher revenue and earnings than Esperion Therapeutics. Kiniksa Pharmaceuticals is trading at a lower price-to-earnings ratio than Esperion Therapeutics, indicating that it is currently the more affordable of the two stocks.
Kiniksa Pharmaceuticals has a net margin of -2.36% compared to Esperion Therapeutics' net margin of -29.37%. Esperion Therapeutics' return on equity of 0.00% beat Kiniksa Pharmaceuticals' return on equity.
Esperion Therapeutics has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500. Comparatively, Kiniksa Pharmaceuticals has a beta of 0.32, indicating that its stock price is 68% less volatile than the S&P 500.
In the previous week, Esperion Therapeutics had 4 more articles in the media than Kiniksa Pharmaceuticals. MarketBeat recorded 13 mentions for Esperion Therapeutics and 9 mentions for Kiniksa Pharmaceuticals. Kiniksa Pharmaceuticals' average media sentiment score of 0.75 beat Esperion Therapeutics' score of 0.22 indicating that Kiniksa Pharmaceuticals is being referred to more favorably in the news media.
Summary
Kiniksa Pharmaceuticals beats Esperion Therapeutics on 11 of the 18 factors compared between the two stocks.
Get Esperion Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Esperion Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ESPR) was last updated on 2/17/2025 by MarketBeat.com Staff